Given the high prevalence of BRAF(V600E) in cancer genomes, Tsai et al.[21] resolved its high-resolution crystal structure and further utilized a structure-guided drug discovery approach to identify a potent and selective small molecule inhibitor of BRAF(V600E), PLX4720. The gene discussed is BRAF; the disease is cancer.